Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 14/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.49 |
| ▸ | ESRRB | O95718 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886143 | 0.93 | ESR1 (0.57) | ESR1ESR2ESRRBPTGS2FOLH1 | |
| SCHEMBL4887868 | 0.91 | ESR1 (0.56) | ESR1ESR2CYP19A1 | |
| SCHEMBL4667995 | 0.81 | ESR1 (0.62) | ESR1ESR2CYP19A1 | |
| SCHEMBL4897738 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2PPARGPPARAFOLH1 | |
| SCHEMBL4667736 | 0.79 | ESR1 (0.58) | ESR1ESR2CYP19A1 | |
| SCHEMBL4665856 | 0.76 | CYP19A1 (0.60) | ESR1ESR2CYP19A1ESRRB | |
| SCHEMBL2556069 | 0.76 | SMN1; SMN2 (0.56) | SMN1; SMN2PPARGPPARAFOLH1 | |
| SCHEMBL4796083 | 0.75 | ESR1 (0.53) | ESR1ESR2CYP19A1 | |
| SCHEMBL4665812 | 0.74 | ESR1 (0.60) | ESR1ESR2CYP19A1PTGS2PPARG | |
| SCHEMBL4895944 | 0.74 | SMN1; SMN2 (0.55) | SMN1; SMN2PPARGPPARAFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | KATAMREDDY SUBBA REDDY | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255078-A1 | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators | GPER1, ESR2, ESRRG | ESR1 4/4885ESR2 2/4885CYP19A1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.